Edition:
United Kingdom

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

388.33USD
18 Sep 2018
Change (% chg)

-- (--)
Prev Close
$388.33
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
293,724
52-wk High
$477.00
52-wk Low
$281.89

Latest Key Developments (Source: Significant Developments)

FDA To Review Supplemental Biologics License Application
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Regeneron Pharmaceuticals Inc ::FDA TO REVIEW SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR PRALUENT® (ALIROCUMAB) INJECTION AS POTENTIAL TREATMENT TO REDUCE MAJOR ADVERSE CARDIOVASCULAR EVENTS.REGENERON PHARMACEUTICALS INC - FDA SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE OF APRIL 28, 2019.  Full Article

Regeneron & Bluebird Bio To Collaborate To Develop New Cell Therapies For Cancer
Monday, 6 Aug 2018 

Aug 6 (Reuters) - bluebird bio Inc ::REGENERON AND BLUEBIRD BIO ANNOUNCE COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE NEW CELL THERAPIES FOR CANCER.REGENERON PHARMACEUTICALS INC - WILL ALSO MAKE A $100 MILLION INVESTMENT IN BLUEBIRD BIO COMMON STOCK AT A PRICE OF $238.10 PER SHARE.REGENERON PHARMACEUTICALS - CO, BLUEBIRD BIO SELECTED 6 INITIAL TARGETS, WILL EQUALLY SHARE COSTS OF RESEARCH AND DEVELOPMENT UP TO POINT OF SUBMITTING IND APPLICATION.  Full Article

Bluebird Bio And Regeneron Announce Collaboration To Discover, Develop And Commercialize New Cell Therapies For Cancer
Monday, 6 Aug 2018 

Aug 6 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO AND REGENERON ANNOUNCE COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE NEW CELL THERAPIES FOR CANCER.BLUEBIRD BIO - CO, REGENERON WILL SPECIFICALLY LEVERAGE REGENERON'S VELOCISUITE PLATFORM TECHNOLOGIES FOR DISCOVERY OF FULLY HUMAN ANTIBODIES.BLUEBIRD BIO - CO, REGENERON HAVE SELECTED 6 TARGETS & WILL EQUALLY SHARE COSTS OF RND UP TO POINT OF SUBMITTING AN INVESTIGATIONAL NEW DRUG APPLICATION.  Full Article

Regeneron Reports Q2 EPS $4.82
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Regeneron Pharmaceuticals Inc ::Q2 2018 EYLEA (AFLIBERCEPT) INJECTION U.S. NET SALES INCREASED 8 PCT TO $992 MILLION VERSUS Q2 2017.REGENERON REPORTS SECOND QUARTER 2018 FINANCIAL AND OPERATING RESULTS.Q2 GAAP EARNINGS PER SHARE $4.82.Q2 EARNINGS PER SHARE VIEW $4.70 -- THOMSON REUTERS I/B/E/S.QTRLY TOTAL REVENUES $1,608 MILLION VERSUS $1,470 MILLION.SEES 2018 CAPEX $410 MILLION TO $450 MILLION.Q2 REVENUE VIEW $1.56 BILLION -- THOMSON REUTERS I/B/E/S.QTRLY NON-GAAP NET INCOME PER SHARE $ 5.45.QTRLY TOTAL NET PRODUCT SALES RECORDED BY SANOFI FOR PRALUENT $32 MILLION.QTRLY TOTAL NET PRODUCT SALES RECORDED BY SANOFI FOR DUPIXENT $28 MILLION.  Full Article

Intellia Therapeutics, Regeneron Agreed To Co-Development Agreement
Friday, 20 Jul 2018 

July 20 (Reuters) - Intellia Therapeutics Inc ::INTELLIA THERAPEUTICS - CO, REGENERON AGREED TO CO-DEVELOPMENT/CO-PROMOTION AGREEMENT CONSISTENT WITH A CERTAIN SCHEDULE OF THEIR APRIL 2016 COLLABORATION DEAL.INTELLIA THERAPEUTICS SAYS CO, REGENERON ENTERED INTO FIRST CO-DEVELOPMENT/CO-PROMOTION AGREEMENT DIRECTED TO A TARGET, WHICH IS TRANSTHYRETIN - SEC FILING.  Full Article

Sanofi announes some positive Phase 3 trials for Dupixent® (dupilumab)
Wednesday, 16 May 2018 

May 16 (Reuters) - Sanofi ::* Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis.* U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018 .* A pivotal Phase 3 trial evaluating Dupixent (®)(dupilumab) to treat moderate-to-severe atopic dermatitis in adolescents (ages 12-17) met its primary and key secondary endpoints.* In the trial, treatment with Dupixent as monotherapy significantly improved measures of overall disease severity, skin clearing, itching, and certain health-related quality of life measures.* Dupixent is the first and only biologic to show positive results in this patient population, adds Sanofi.  Full Article

Regeneron Says FDA To Conduct Priority Review Of Cemiplimab As A Potential Treatment For Advanced Cutaneous Squamous Cell Carcinoma
Monday, 30 Apr 2018 

April 30 (Reuters) - Regeneron Pharmaceuticals Inc ::FDA TO CONDUCT PRIORITY REVIEW OF CEMIPLIMAB AS A POTENTIAL TREATMENT FOR ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA.SAYS TARGET ACTION DATE FOR FDA DECISION IS OCTOBER 28, 2018..  Full Article

Regeneron Announces Approval Of Dupixent (Dupilumab) In Japan For Treatment Of Atopic Dermatitis
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Regeneron Pharmaceuticals Inc ::REGENERON ANNOUNCES APPROVAL OF DUPIXENT® (DUPILUMAB) IN JAPAN FOR THE TREATMENT OF ATOPIC DERMATITIS.REGENERON PHARMACEUTICALS - DUPIXENT IS BEING JOINTLY DEVELOPED BY CO, SANOFI UNDER A COLLABORATION AGREEMENT, & WILL BE COMMERCIALIZED IN JAPAN BY SANOFI.  Full Article

Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data From Pivotal Phase 3 Palisade Trial Of AR101 For Peanut Allergy
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS - PALISADE COMPLETED IN 2017; TOPLINE RESULTS ANTICIPATED IN FEBRUARY.AIMMUNE THERAPEUTICS INC - AR101 BLA SUBMISSION EXPECTED AT END OF 2018.AIMMUNE THERAPEUTICS ANNOUNCES 2018 OUTLOOK, INCLUDING UPCOMING DATA FROM PIVOTAL PHASE 3 PALISADE TRIAL OF AR101 FOR PEANUT ALLERGY.AIMMUNE THERAPEUTICS - ARTEMIS TRIAL IS ON TRACK TO COMPLETE ENROLLMENT IN Q1 OF 2018, EXPECTS DATA FROM ARTEMIS IN EARLY 2019.AIMMUNE THERAPEUTICS INC - ENDED 2017 WITH ABOUT $182 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF DEC 31, 2017.AIMMUNE THERAPEUTICS INC- 2018 PLANS INCLUDE INITIATION OF ARC005 CLINICAL TRIAL OF AR101 FOR PEANUT ALLERGY IN YOUNG CHILDREN AGES 6-48 MONTHS.AIMMUNE THERAPEUTICS - 2018 PLANS ALSO INCLUDE INITIATION, WITH REGENERON AND SANOFI, OF PHASE 2 CLINICAL TRIAL OF AR101 AND ADJUNCTIVE DUPILUMAB.AIMMUNE - ALSO EXPECTS TO FILE IND APPLICATION FOR EGG ALLERGY PROGRAM IN 2018, CONTINUE WORK TOWARD FILING IND FOR WALNUT ALLERGY IN 2019.  Full Article

Regeneron Pharma Says Enter Letter Agreement Relating To Immuno-Oncology License,Collaboration Agreement With Sanofi
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Regeneron Pharmaceuticals Inc ::REGENERON PHARMACEUTICALS-ON JAN 7,ENTERED LETTER AGREEMENT RELATING TO IMMUNO-ONCOLOGY LICENSE,COLLABORATION AGREEMENT WITH SANOFI BIOTECHNOLOGY SAS​.REGENERON PHARMACEUTICALS-PURSUANT TO LETTER AGREEMENT, CO, SANOFI SAS, AGREED TO INCREASE REGN2810 BUDGET AMOUNT TO $1.640 BILLION.REGENERON -ENTERED LETTER AGREEMENT ALSO RELATING TO AMONG OTHERS​, THE INVESTOR AGREEMENT DATED AS OF JAN 11, 2014, WITH SANOFI - SEC FILING.REGENERON PHARMACEUTICALS INC - ‍ ALSO AGREED TO REVISE REGN2810 GLOBAL DEVELOPMENT PLAN AND REGN2810 GLOBAL DEVELOPMENT BUDGET.  Full Article

Photo

Sanofi pledges to keep up its restructuring efforts

(This version of the Sept. 14th story has been refiled to add dropped words in fifth paragraph)